{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:18:27Z","timestamp":1791584307867,"version":"4.3.4"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma is the third leading cause of cancer death. Currently, sorafenib is the treatment of choice in advanced hepatocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>Assessing the effectiveness and toxicity of sorafenib in real-word clinical practice in patients with hepatocarcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings and Design:<\/jats:title>\n                    <jats:p>Single-centered observational retrospective study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Material:<\/jats:title>\n                    <jats:p>We included patients with hepatocarcinoma who began treatment with sorafenib between 2008 and 2018. We evaluated overall survival, time to progression, and response using RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Toxicity was assessed according to the Common Terminology Criteria for Adverse Events version 5. 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Statistical Analysis Used:<\/jats:title>\n                    <jats:p>Kaplan\u2013Meier curves and the log-rank test were used to determine the survival time and estimate factors associated with these events. Data were analyzed with SPSS 19.0 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We included 36 patients (88.9% male) with an average age of 64 \u00b1 3.4 years. The tumor stage was advanced (C) in 21 patients (61.8%). We obtained a median overall survival of 8.5 months (IQR 3.14\u201318.9) and a time to progression of 4.5 months (IQR 2.4\u20138.8). The main degree of response was progression in 19 patients (36.1%), followed by stable disease in 13 (52.8%). The most commonly reported adverse reactions were: constitutional (83.3%), gastrointestinal (55%) and dermatological symptoms (50.0%). The development of grades 3 or 4 toxicity was not associated with increased overall survival (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.719).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The findings of the survival analysis obtained in real practice are similar to those obtained in pivotal clinical trials. Adverse reactions were different from those expected.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_308_21","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T08:01:24Z","timestamp":1695196884000},"page":"1345-1349","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Real-world evidence of sorafenib for the treatment of hepatocellular carcinoma: A single-center study"],"prefix":"10.4103","volume":"19","author":[{"given":"Aida","family":"Lopez-Lopez","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University Hospital Complex of Vigo, SERGAS-UVIGO, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Gayoso-Rey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Hospital Complex of Vigo, SERGAS-UVIGO, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Garcia-Beloso","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Hospital Complex of Vigo, SERGAS-UVIGO, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaiza","family":"Romero-Ventosa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Hospital Complex of Vigo, SERGAS-UVIGO, Spain"},{"name":"NeumoVigo I+i Research Group, SERGAS-UVIGO, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Robles-Torres","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Hospital Complex of Vigo, SERGAS-UVIGO, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Martinez-Reglero","sequence":"additional","affiliation":[{"name":"Methodology and Statistics Unit, Galicia Sur Health Research Institute, SERGAS-UVIGO, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Pi\u00f1eiro-Corrales","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University Hospital Complex of Vigo, SERGAS-UVIGO, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"511.e1","DOI":"10.1016\/j.medcli.2016.01.028","article-title":"Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH","volume":"146","author":"Forner","year":"2016","journal-title":"Med Clin (Barc)"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.medcli.2016.12.048","article-title":"Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008\u20132009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers","volume":"149","author":"Rodr\u00edguez de Lope","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"302","DOI":"10.6004\/jnccn.2019.0019","article-title":"Guidelines Insights:Hepatobiliary Cancers, Version 2.2019","volume":"17","author":"Benson","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R4-20241021"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"16","DOI":"10.14740\/gr1109","article-title":"Sorafenib-related adverse events in predicting the early radiologic responses of hepatocellular carcinoma","volume":"12","author":"Lee","year":"2019","journal-title":"Gastroenterol Res"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/1756283X15618129","article-title":"Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib","volume":"9","author":"Granito","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/00365521.2016.1166518","article-title":"Sorafenib in the treatment of hepatocellular carcinoma:A multi-centre real-world study","volume":"51","author":"Doyle","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2478\/raon-2020-0027","article-title":"Sorafenib for the treatment of hepatocellular carcinoma:A single-centre real-world study","volume":"54","author":"Hanzel","year":"2020","journal-title":"Radiol Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_308_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:41:34Z","timestamp":1787067694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_308_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_308_21","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]},"assertion":[{"value":"2021-02-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}